NCT05786768View on ClinicalTrials.gov

Efficacy and Safety of Obinutuzumab Versus Rituximab in Childhood Steroid Dependant and Frequent Relapsing Nephrotic Syndrome

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

88

Participants

Timeline

Start Date

October 18, 2023

Primary Completion Date

October 18, 2027

Study Completion Date

December 31, 2027

Conditions
Steroid-Dependent Nephrotic SyndromeSteroid-Sensitive Nephrotic Syndrome
Interventions
DRUG

single infusion of Rituximab

single infusion of Rituximab 375 mg/m2

DRUG

single infusion of Obinutuzumab

single infusion of Obinutuzumab 300mg/1.73 m2

Trial Locations (1)

75019

RECRUITING

Robert Debre Hospital, Paris

All Listed Sponsors
lead

Assistance Publique - Hôpitaux de Paris

OTHER